Patents Assigned to University of Queensland
  • Single chain relaxin polypeptides
    Patent number: 9359422
    Abstract: The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: June 7, 2016
    Assignees: The University of Queensland, Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Karl Johan Rosengren, Linda Maria Haugaard-Kedstrom, Ross Alexander David Bathgate, Mohammed Akhter Hossain, John Desmond Wade, Andrew Lawrence Gundlach, Andrew J. Lawrence
  • Patch production
    Patent number: 9283365
    Abstract: A method of producing projections on a patch including providing a mask on a substrate and etching the substrate using an etchant and a passivant to thereby control the etching process and form the projections, wherein the passivant does not include oxygen.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: March 15, 2016
    Assignee: The University of Queensland
    Inventors: Mark Anthony Fernance Kendall, Derek William Kenneth Jenkins
  • Method of inducing an immune response
    Patent number: 9260715
    Abstract: A method is provided for inducing or enhancing an immune response in a mammal to a target polypeptide expressed in a plurality of cells of the mammal, which method comprises administering to the mammal an inhibitory nucleic acid which targets a region of a ribonucleic acid (RNA) which encodes said polypeptide. Also provided is a pharmaceutical composition comprising an inhibitory nucleic acid which targets a region of an RNA which encodes a target polypeptide expressed in a plurality of cells of a mammal, such that translation of an aberrant form of the target polypeptide occurs in said cells, said truncated form of the target polypeptide comprising one or more T cell epitopes; together with a pharmaceutically acceptable carrier or diluent.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: February 16, 2016
    Assignee: The University of Queensland
    Inventors: Nigel McMillan, Graham Leggatt, Wenyi Gu
  • Compositions comprising E-selectin antagonists and uses therefor
    Patent number: 9254322
    Abstract: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: February 9, 2016
    Assignee: The University of Queensland
    Inventors: Jean-Pierre Levesque, Ingrid Winkler
  • CELL-FREE BIOFRAGMENT COMPOSITIONS AND RELATED SYSTEMS, DEVICES, AND METHODS
    Publication number: 20150377880
    Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.
    Type: Application
    Filed: December 10, 2013
    Publication date: December 31, 2015
    Applicants: Seattle Biomedical Research Institute, The University of Queensland
    Inventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J.A. Shiddiky, Matt Trau
  • Coating method
    Patent number: 9220678
    Abstract: A method of coating a material onto projections provided on a patch. The method includes applying a coating solution containing the material to at least the projections and drying the coating solution to at least the projections using a gas flow.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: December 29, 2015
    Assignee: The University of Queensland
    Inventors: Mark Anthony Fernance Kendall, Germain Fernando, Xianfeng Chen, Tarl Prow
  • Haematopoietic-prostaglandin D2 synthase inhibitors
    Patent number: 9199976
    Abstract: The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: December 1, 2015
    Assignee: The University of Queensland
    Inventors: Mark Leslie Smythe, Jack Urquhart Flanagan
  • Device and method for preparing microparticles
    Patent number: 9157054
    Abstract: The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: October 13, 2015
    Assignee: The University of Queensland
    Inventor: Bhesh Bhandari
  • Mutant bacterial glycoproteins and uses thereof
    Patent number: 9150621
    Abstract: The present invention relates to the use of mutant glycoproteins from pathogenic bacteria lacking one or more phosphorylcholine and/or glycosylation post-translational modifications as immunogens. These post-translational modifications act as masking structures that elicit an immune response which does not confer protection on an infected individual. The removal or modification of these masking structures alters the protein such that it elicits a stronger immune response to the protein and/or the bacterial pathogen. Particular examples are pilin proteins and nitrite reductase glycoproteins of Neisseria bacteria.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: October 6, 2015
    Assignee: The University of Queensland
    Inventor: Michael Paul Jennings
  • Wastewater Refinery
    Publication number: 20150274562
    Abstract: A wastewater refinery comprising one or more electrodialytic cells with mono-, di-, or multi-valent selective membranes interspersed with one or more concentrate compartments to selectively recovery ions from wastewater. The wastewater refinery may harvest ions by utilising techniques including ion selective resins and pervaporation.
    Type: Application
    Filed: October 14, 2013
    Publication date: October 1, 2015
    Applicants: Grains Research & Development Corporation, The University of Queensland
    Inventors: Damien Batstone, Chirag Mehta
  • J-superfamily conotoxin peptides
    Patent number: 9062118
    Abstract: The invention relates to relatively short peptides (termed J-Superfamily conotoxin peptides, J-conotoxins or J-conotoxin peptides herein), about 25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The J-conotoxins are useful for treating disorders involving voltage gated ion channels and/or receptors.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: June 23, 2015
    Assignees: University of Utah Research Foundation, The University of Queensland, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Julita S. Imperial, Baldomero M. Olivera, Paul F. Alewood, Heinz Terlau, David J. Craik, Estuardo Lopez-Vera, Pradip K. Bandyopadhyay
  • METHOD AND COMPOSITION FOR DELIVERING A COMPOUND THROUGH A BIOLOGICAL BARRIER
    Publication number: 20150150788
    Abstract: A method for delivering a compound through a biological barrier including applying a force to a plurality of microparticles on a surface of the barrier so that at least some of the microparticles penetrate the biological barrier to facilitate delivery of the compound therethrough.
    Type: Application
    Filed: June 21, 2013
    Publication date: June 4, 2015
    Applicant: The University of Queensland
    Inventors: Tarl W. Prow, H. Peter Soyer
  • Compositions and methods for modulating immune responses
    Patent number: 9017697
    Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: April 28, 2015
    Assignee: The University of Queensland
    Inventors: Ranjeny Thomas, Nigel Meredith Davies, Brendan John O'Sullivan
  • Surface structure modification
    Patent number: 8977085
    Abstract: A method of forming an optical fiber tip, the method including, roughening at least part of an end portion of the optical fiber; and, etching the roughed end portion to thereby form an optical fiber tip.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: March 10, 2015
    Assignee: The University of Queensland
    Inventors: Laurence James Walsh, Roy George
  • DESIGNED BIOSURFACTANTS, THEIR MANUFACTURE, PURIFICATION AND USE
    Publication number: 20150031600
    Abstract: The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in modulating the stability of a foam, alone or in combination with an ?-helical peptide. The designed polypeptide biosurfactant may be useful in the formation and collapse of foams in foods, beverages, pharmaceuticals, personal care products, cosmetics, cleaning products, mineral recovery, bioremediation, oil recovery and laundry products. The designed biosurfactants may also be useful in recombinant production and purification of peptides, polypeptides and proteins.
    Type: Application
    Filed: December 14, 2011
    Publication date: January 29, 2015
    Applicant: The University of Queensland
    Inventors: Anton Peter Jacob Middelberg, Mirjana Dimitrijev-Dwyer, Michael Brech
  • Modulations of protease activated receptors
    Patent number: 8927503
    Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: January 6, 2015
    Assignee: The University of Queensland
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
  • Nociceptin mimetics
    Patent number: 8921306
    Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 30, 2014
    Assignee: The University of Queensland
    Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
  • Modulations of protease activated receptors
    Patent number: 8901085
    Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: December 2, 2014
    Assignee: The University of Queensland
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
  • Patch production
    Patent number: 8883015
    Abstract: A method of producing projections on a patch including providing a mask on a substrate and etching the substrate using an etchant and a passivant to thereby control the etching process and form the projections, wherein the passivant does not include oxygen.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: November 11, 2014
    Assignee: The University of Queensland
    Inventors: Mark Anthony Fernance Kendall, Derek William Kenneth Jenkins
  • PREVENTION AND TREATMENT OF ACUTE INFLAMMATORY CONDITIONS
    Publication number: 20140329761
    Abstract: The present invention relates generally to methods for the prevention and treatment of acute inflammatory conditions in individuals using an agonist of the complement C3a receptor.
    Type: Application
    Filed: June 20, 2012
    Publication date: November 6, 2014
    Applicant: The University of Queensland
    Inventors: Trent Martin Woodruff, Stephen Maxwell Taylor